Mattersight Corporation (NASDAQ:MATR) shares fell -0.60% in last trading session and ended the day at $6.68. MATR Gross Margin is 72.80% and its has a return on assets of -37.40%. Mattersight Corporation (NASDAQ:MATR) quarterly performance is -2.05%.
On 7 December, it was reported Mattersight Corporation (NASDAQ: MATR), announced that it has recently received a new patent related to its behavioral analytics solution, which leverages advanced linguistic algorithms with consumer behavioral data to improve customer call center interactions, employee performance and business outcomes.
Towers Watson & Co. (NASDAQ:TW) ended the last trading day at $132.96. Company weekly volatility is calculated as 4.00% and price to cash ratio as 12.16. Towers Watson & Co. (NASDAQ:TW) showed a weekly performance of -1.51%.
Willis Group Holdings (WSH) and Towers Watson (NASDAQ:TW) have announced the preliminary results of their respective special meetings of shareholders that were held earlier today. Shareholders of each company approved the proposals necessary to complete the merger of equals transaction. The companies expect that the transaction will close very early in the New Year, subject to customary closing conditions, including the receipt of certain regulatory approvals.
On 11 December, Benitec Biopharma Limited (NASDAQ:BNTC) shares increased 0.67% and was closed at $4.52. Benitec Biopharma Limited (NASDAQ:BNTC) year to date (YTD) performance is -70.95%.
Benitec Biopharma Limited (NASDAQ: BNTC) announced that the Company will host a conference call and live audio webcast on Tuesday, December 15, 2015, at 4:30 pm ET/ Wednesday, December 16, at 8.30am AEST, to provide an operational update. Interim CEO, Greg West will provide an overview of Benitec’s current and planned corporate and clinical activities.
InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) shares fell -2.58% in last trading session and ended the day at $7.18. NVIV has a return on assets of -155.40%. InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) quarterly performance is -27.98%.
On 3 December, InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) announced it has received conditional approval of a study protocol amendment from the U.S. Food and Drug Administration (FDA) that will convert its ongoing pilot study into a pivotal probable benefit study. The approval is conditional solely upon a minor change to the informed consent form that has already been submitted to the FDA. Full approval of the amendment is expected in the next 30 days.
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) caters to the Healthcare space. Its weekly performance is -23.23%. On the last day of trading company shares ended up at $1.19. Pluristem Therapeutics, Inc. (NASDAQ:PSTI) distance from 50-day simple moving average (SMA50) is -32.30%.
Pluristem Therapeutics Inc. (NASDAQ: PSTI) announced that it received a notice today from United Therapeutics Corporation (“United”) ending its licensing agreement for the development of PLX-PAD for the treatment of pulmonary arterial hypertension (PAH). According to the licensing agreement Pluristem will regain full rights to PLX-PAD in this indication, as well as all clinical data and regulatory submissions, allowing Pluristem to move forward with the clinical development of the program and seek other licensing partners.
Leave a Reply